Bioxytran (BIXT) Assets Average (2011 - 2026)
Bioxytran (BIXT) posted Assets Average of $636902.5 for Q1 2026, up 56.32% sequentially from $407423.0 in Q4 2025, and up 363.63% YoY from $137373.0 in Q1 2025.
Bioxytran (BIXT) Assets Average (2011 - 2026) Analysis & Trends
Bioxytran has reported Assets Average for 16 years, with the latest figure at $636902.5 in Q1 2026.
- Quarterly Assets Average rose 363.63% year-over-year to $636902.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $636902.5 (up 363.63% YoY) and the FY2025 annual result came in at $398623.0, up 186.7% from the prior year.
- Assets Average climbed to $636902.5 in Q1 2026 per BIXT's latest filing, from $407423.0 in the prior quarter.
- Over five years, Assets Average peaked at $688076.0 in Q2 2022 and troughed at $127046.5 in Q2 2024.
- A 5-year average of $289300.7 and a median of $166052.0 in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2026: Assets Average tumbled 72.63% in 2023, then jumped 363.63% in 2026.
- Over 5 years, Assets Average stood at $409737.5 in 2022, then plunged by 59.92% to $164212.5 in 2023, then slipped by 9.35% to $148851.0 in 2024, then soared by 173.71% to $407423.0 in 2025, then soared by 56.32% to $636902.5 in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $636902.5, $407423.0, and $151897.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 474,323.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 636,902.50 |
| Dec 31, 2025 | 407,423.00 |
| Sep 30, 2025 | 151,897.50 |
| Jun 30, 2025 | 141,776.50 |
| Mar 31, 2025 | 137,373.00 |
| Dec 31, 2024 | 148,851.00 |
| Sep 30, 2024 | 143,780.50 |
| Jun 30, 2024 | 127,046.50 |
| Mar 31, 2024 | 132,461.00 |
| Dec 31, 2023 | 164,212.50 |
| Sep 30, 2023 | 166,052.00 |
| Jun 30, 2023 | 188,297.00 |
| Mar 31, 2023 | 302,234.50 |
| Dec 31, 2022 | 409,737.50 |
| Sep 30, 2022 | 508,382.00 |
| Jun 30, 2022 | 688,076.00 |
| Mar 31, 2022 | 463,608.50 |
| Dec 31, 2021 | 440,769.00 |
| Sep 30, 2021 | 834,272.50 |
| Jun 30, 2021 | 645,800.00 |